Cytokinetics

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cytokinetics focuses on aficamten development post-FDA action, eyes international growth

Cytokinetics is navigating challenges post-CRL for omecamtiv mecarbil while focusing on aficamten's development.
Financially, the company is balancing increased expenses with revenue growth and strategic investments in R&D.
Key milestones for 2023 include FDA meetings for omecamtiv mecarbil and data expectations for aficamten.
The company's emphasis on aficamten's differentiation and clinical progress signals a strategic shift in focus.

Cytokinetics shifts focus to cardiovascular pipeline, optimistic outlook ahead

Cytokinetics focusing on cardiovascular pipeline progress, redirecting resources.
Optimistic outlook for aficamten and other cardiovascular drug candidates.
Financially stable with cash reserves and strategic cost-saving measures.

Cytokinetics reports strong Q2 progress, eyes market expansion opportunities

Cytokinetics made significant strides in Q2 2023, advancing key studies and reducing operating spending to enhance financial stability.
Positive data and progress in cardiovascular therapies showcase the company's potential in treating HCM and positioning in the market.
While facing challenges in stock performance and data disclosures, Cytokinetics remains poised for growth with opportunities in novel therapies and market expansion.

Cytokinetics excels in Q3 with aficamten progress and commercial readiness

Cytokinetics demonstrated strong operational and financial performance in Q3 2023, with a focus on advancing the aficamten program and preparing for potential commercialization.
While facing challenges related to data interpretation complexities and real-world beta blocker usage, the company remains well-positioned with compelling clinical aspects of aficamten.
Opportunities lie in potential partnerships for capital access, broad market potential across regions, and upcoming data disclosures driving market differentiation.

Cytokinetics excels with positive aficamten trial results and strategic focus

Cytokinetics' Q4 2023 marked a significant milestone with positive aficamten trial results, strong financial standing, and strategic focus on regulatory advancements and market expansion.
The company's strengths lie in aficamten's efficacy, financial stability, and potential for differentiated labeling, while challenges include adoption transitions and data analysis complexities.
Opportunities abound in accelerating NDA submission, expanding patient reach, engaging with payors, and leveraging data insights for enhanced patient outcomes and market positioning.
Overall, Cytokinetics is poised for growth and impact in 2024, with a clear roadmap for success in advancing aficamten and maximizing its therapeutic potential in the HCM market.

Cytokinetics advances aficamten for HCM treatment amid financial strength

Cytokinetics is making significant strides in advancing aficamten for HCM treatment, supported by positive results and regulatory engagements.
The company's financial strength and strategic focus on commercial readiness position it well for future growth and market penetration.
Challenges lie in addressing unmet needs in pediatric HCM, enrollment completion for ongoing trials, and establishing treatment credibility.
Opportunities exist in expanding diagnosis potential, developing competitive treatment options, and enhancing regulatory alignment for global market access.

Cytokinetics advances obstructive HCM treatment with strong financials and strategic focus

Cytokinetics is poised for growth with FDA submission for aficamten and strong financial position.
Strategic focus on commercial preparations and clinical trials signals a commitment to future success.
Challenges in market competition and education require targeted efforts for successful product launch.
Emphasis on patient-centric approach and category expansion positions the company for market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cytokinetics (CYTK) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to loss of $1.34 per share a year ago.

Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates

Type B Meeting Held with FDA Related to Potential Risk Mitigation Strategies for Aficamten; Company Has Initiated Rolling NDA Submission

Cytokinetics Reports Second Quarter 2024 Financial Results

Program Augments Existing Patient Advocacy and Professional Society Donations to Non-Profit Organizations Aligned with Corporate Values

Cytokinetics Announces Call for Proposals for Corporate Giving Program

SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 8, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company's outlook for the future.

Cytokinetics to Announce Second Quarter Results on August 8, 2024

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

HCM is a genetic disorder causing thickened heart muscles, potentially leading to severe symptoms and complications. Standard treatments include beta-blockers and calcium channel blockers, with new drugs like mavacamten and aficamten emerging. Cytokinetics' aficamten shows promise compared to mavacamten but faces competitive challenges and market uncertainties.

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

SOUTH SAN FRANCISCO, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 28, 2024 it granted stock options to purchase an aggregate of 48,453 shares of common stock, 31,460 restricted stock units (RSUs), and 5,537 performance stock units (PSUs) that, if earned, will be settled in shares of common stock upon vesting to 10 employees, whose employment commenced in June 2024, as a material inducement to their employment.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

AstraZeneca

Boston Scientific

Corcept Therapeutics

Crinetics Pharmaceuticals Inc

Jazz Pharmaceuticals

Zoetis

While innovations such as artificial intelligence have become all the rage, there's another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven't considered the sector, it's really time to focus on biotech stocks.

7 Biotech Stocks to Boost Your Portfolio to Peak Health

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 study evaluating the pharmacokinetics, safety and tolerability of aficamten in healthy Japanese and Caucasian participants.

Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in June:

Cytokinetics to Participate in June Investor Conferences

Arvinas Inc

Axsome Therapeutics

Intellia Therapeutics

Novartis

Pfizer

Regeneron Pharmaceuticals

Viking Therapeutics

Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share. The gross proceeds to Cytokinetics from the offering, before offering expenses payable by Cytokinetics, were approximately $500 million.

Cytokinetics Announces Closing of Public Offering of Common Stock

Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.

Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the pricing of an underwritten public offering of 9,803,922 shares of its common stock at a price to the public of $51.00 per share, before underwriting discounts and commissions. The gross proceeds to Cytokinetics from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Cytokinetics, are expected to be approximately $500 million. The offering is expected to close on May 28, 2024, subject to customary closing conditions. Additionally, Cytokinetics has granted the underwriters a 30-day option to purchase up to an additional 1,470,588 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock in the offering will be sold by Cytokinetics.

Cytokinetics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced plans to offer, subject to market and other conditions, approximately $500 million of shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Cytokinetics expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. All of the shares of common stock in the offering will be sold by Cytokinetics.

Cytokinetics Announces Proposed Public Offering of Common Stock

Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances Its Specialty Cardiology Franchise Deal Provides Cytokinetics with Diversified Access to Capital as Company Advances Its Specialty Cardiology Franchise

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

SOUTH SAN FRANCISCO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the Company will host the muscle biology-focused Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) today, May 17th, 2024 at the Mission Bay Conference Center in San Francisco.

Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology

SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations related to aficamten at the European Society of Cardiology Congress 2024, taking place in London, UK from August 30, 2024 – September 2, 2024.

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024

Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. But Cytokinetics stock slipped Monday.

Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day

Statistically Significant and Clinically Meaningful Improvements Observed in Primary Efficacy Endpoint and All Secondary Endpoints; Results Consistent Across All Prespecified Subgroups

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

Analyses of SEQUOIA-HCM Elaborate on Dosing and Measures of Safety During Treatment with Aficamten Results from Cardiopulmonary Exercise Testing Showed Improvement in Exercise Performance were Strongly Correlated to Other Measures of Clinical Improvement Company to Host Investor Event and Webcast Today at  4:00 PM Western European Summer Time (11:00 AM Eastern Time) SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of A ficamten in HCM), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), elaborating on dosing and safety data as well as the effect of aficamten on exercise performance were presented at Heart Failure 2024, an International Congress of the European Society of Cardiology.

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

Cytokinetics, Incorporated (NASDAQ:CYTK ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Diane Weiser - SVP of Corporate Communication and IR Robert Blum - President and CEO Fady Malik - EVP of R&D Stuart Kupfer - SVP and Chief Medical Officer Andrew Callos - EVP and Chief Commercial Officer Robert Wong - VP and Chief Accounting Officer Conference Call Participants Paul Choi - Goldman Sachs Srikripa Devarakonda - Truist Securities Tessa Romero - JPMorgan Roanna Ruiz - Leerink Salim Syed - Mizuho Jeff Hung - Morgan Stanley Mayank Mamtani - B. Riley Securities Jason Butler - Citizens JMP Cameron Bozdog - BofA Carter Gould - Barclays Yasmeen Rahimi - Piper Sandler Serge Belanger - Needham Ashwani Verma - UBS Sean McCutcheon - Raymond James Operator Good afternoon.

Cytokinetics, Incorporated (CYTK) Q1 2024 Earnings Call Transcript

Cytokinetics (CYTK) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.38 per share a year ago.

Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates

Primary Results and Two Additional Analyses from SEQUOIA-HCM to be Presented in a Late-Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

Cytokinetics Reports First Quarter 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with A ficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in development for the potential treatment of HCM.

Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy

News for Cytokinetics Stock (CYTK)